Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Seoul
Clinical trial register · South Korea

Clinical Trials in Seoul, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 58 Daegu 16 Goyang-si 12 Seongnam 12 Busan 9
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Seoul National University Hospital183 Yonsei University143 Samsung Medical Center142 Merck Sharp & Dohme LLC111 Clear sponsor filter
Site location
Seoul58 Daegu16 Goyang-si12 Seongnam12 Busan9
All 31 locations
Target enrolment
to

Trials with a site in Seoul

58 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Pfizer
Phase 3
954
Daejeon, Anyang-si, Yangsan, Incheon, Seoul
2026-06-10
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Pfizer
Phase 1
250
Seoul
2026-04-08
Recruiting
Pfizer
Phase 2/3
1,156
Jeonju, Seoul
2026-02-11
Recruiting
Pfizer
Observational
660
Seoul
2025-11-13
Active, closed
Pfizer
Phase 2
42
Incheon, Seoul
2025-11-10
Recruiting
Pfizer
Phase 1
294
Seoul
2025-11-06
Recruiting
Pfizer
Phase 2
200
Ansan-si, Busan, Seoul
2025-10-30
Recruiting
Pfizer
Phase 2/3
982
Incheon, Seongnam, Seongnam-si, Seoul, Daegu, Busan
2025-10-03
Recruiting
Pfizer
Phase 3
680
Cheongju-si, Goyang-si, Seongnam, Seongnam-si, Suwon, Haeundae-gu, Dongjak-gu, Seoul
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Goyang-si, Seongnam, Seoul, Junggu
2025-09-28
Recruiting
Pfizer
Observational
3,000
Seoul
2025-08-27
Recruiting
Pfizer
Phase 3
6,000
Chuncheon, Gwangju, Seoul, Daegu
2025-08-25
Recruiting
Pfizer
Phase 3
400
Seongnam-si, Gangnam-gu, Seoul
2025-08-05
Recruiting
Pfizer
Phase 3
714
Hwasun-gun, Seongnam, Suwon, Busan, Haeundae-gu, Seoul, Deagu
2025-07-23
Recruiting
Pfizer
Phase 3
300
Namdong-gu, Gwangju, Seoul
2025-07-14
Active, closed
Pfizer
Observational
150
Seoul
2025-06-05
Recruiting
Pfizer
Phase 2
252
Jeonju, Daegu, Seoul
2025-05-20
Recruiting
Pfizer
Phase 3
674
Cheonan-si, Jeonju, Seongnam, Busan, Seoul, Daegu
2025-04-01
Recruiting
Pfizer
Phase 3
723
Hwaseong-si, Gangseo-gu, Seoul
2025-03-11
Active, closed
Pfizer
Phase 3
1,035
Seongnam-si, Incheon, Goyang-si, Seongnam, Gangnam-gu, Seoul
2025-01-06
Recruiting
Pfizer
Phase 3
900
Hwasun, Goyang-si, Seoul, Daegu, Junggu
2024-10-22
Active, closed
Pfizer
Phase 3
600
Hwasun, Goyang-si, Seoul, Daegu
2024-10-21
Active, closed
Pfizer
Observational
660
Seoul
2024-10-11
Active, closed
Pfizer
Observational
565
Seoul
2024-06-20
Recruiting
Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
NCT05754710Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis
DrugXeljanz
Pfizer
Observational
10
Seoul
2024-04-12
Recruiting
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
NCT05733104Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection, Hospital-acquired Pneumonia
Pfizer
Observational
600
Seoul
2024-02-19
Recruiting
Pfizer
Phase 3
492
Seoul
2024-02-08
Active, closed
Pfizer
Phase 3
394
Suwon, Seoul
2024-01-19
Active, closed
Pfizer
Phase 2
333
Suwon, Seoul
2024-01-09
Recruiting
Pfizer
Observational
165
Seoul
2023-12-05
Recruiting
Pfizer
Observational
3,000
Seoul
2023-11-29
Recruiting
Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
NCT05599412Metastatic ALK+ Non Small Cell Lung Cancer
DrugLorviqua
Pfizer
Observational
600
Seoul
2023-05-22
Recruiting
Pfizer
Phase 3
318
Suwon, Seoul, Gwangju
2023-05-20
Active, closed
Pfizer
Phase 3
624
Namdong-gu, Goyang-si, Seongnam, Suwon, Seoul
2023-03-03
Recruiting
Pfizer
Observational
1,100
Seoul
2023-01-07
Recruiting
Pfizer
Phase 3
173
Seoul
2022-12-28
Recruiting
Pfizer
Phase 3
100
Seoul, Daegu
2022-12-09
Recruiting
Pfizer
Phase 3
1,060
Hwasun-gun, Seongnam, Seoul
2022-11-10
Active, closed
Pfizer
Phase 2
35
Goyang-si, Seoul
2022-07-07
Recruiting
Pfizer
Phase 4
210
Seoul
2022-07-05
Active, closed
Pfizer
Phase 3
854
Namdong-gu, Hwasun Gun, Seongnam, Busan, Seoul, Daegu, Junggu
2022-03-25
Active, closed
Korea Comirnaty Post-marketing Surveillance
NCT05032976COVID-19, Vaccines, Adverse Effects, SARS-CoV-2
Pfizer
Observational
12,000
Seoul
2022-03-18
Recruiting
Korean Post-marketing Surveillance for Xeljanz XR
NCT04876781Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis
DrugTofacitinib
Pfizer
Observational
200
Seoul
2022-01-12
Recruiting
Pfizer
Phase 3
245
Seoul, Daegu
2021-11-17
Recruiting
Pfizer
Phase 3
893
Seongnam-si, Hwasun-gun, Busan, Seoul, Daegu, Incheon
2021-10-04
Active, closed
Pfizer
Phase 3
77
Namdong-gu, Goyang-si, Seongnam, Seoul
2021-09-29
Active, closed
Pfizer
Phase 3
599
Goyang-si, Hwasun-gun, Seongnam, Daegu, Seoul
2021-05-12
Active, closed
Pfizer
Phase 2
66
Seoul
2021-04-08
Active, closed
Pfizer
Phase 3
841
Goyang-si, Busan, Daegu, Incheon, Seoul
2020-12-21
Recruiting
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
DrugsPrifetrastat·Atirmociclib·Palbociclib·Letrozole
Pfizer
Phase 2
320
Seongnam-si, Seoul, Daegu
2020-11-16
Active, closed
Pfizer
Phase 3
114
Yangsan, Seoul
2020-11-05
Active, closed
Pfizer
Phase 3
77
Seoul
2020-08-18
Active, closed
Pfizer
Phase 3
1,068
Goyang-si, Seongnam-si, Seoul, Daegu
2019-12-30
Active, closed
Pfizer
Phase 3
51
Seoul
2019-07-29
Recruiting
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
NCT03460977Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
DrugsMevrometostat·Xtandi·Itraconazole·Enzalutamide
Pfizer
Phase 1
453
Seongnam, Seoul, Daejeon
2018-04-17
Active, closed
Pfizer
Phase 3
1,054
Goyang-si, Busan, Daegu, Seoul
2017-12-18
Active, closed
Pfizer
Phase 3
296
Suwon, Seoul, Ulsan
2017-04-27
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Seongnam-si, Yangsan, Hwasun-gun, Incheon, Seoul
2014-12-17
Rows per page Showing 1–58 of 58
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/seoul

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 58 of those studies with a site in Seoul that also match the filters currently applied.

How many clinical trials are recruiting in Seoul?

35 of the 58 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 23 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Seoul), 58 studies
PhaseStudiesRecruitingShare
Phase 3321755.2%
Observational13922.4%
Phase 27312.1%
Phase 1335.2%
Phase 2/3223.4%
Phase 4111.7%

Most active sponsors

Lead sponsors with the most studies (Seoul)
Lead sponsorStudiesRecruiting
Pfizer5835
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.